Immunome, Inc.
IMNM
$27.20
$0.782.95%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 29.12% | -8.64% | |||
| Gross Profit | -29.12% | 8.64% | |||
| SG&A Expenses | 40.93% | 7.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 31.69% | -5.62% | |||
| Operating Income | -31.69% | 5.62% | |||
| Income Before Tax | -35.83% | 22.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -35.83% | 22.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -35.83% | 22.98% | |||
| EBIT | -31.69% | 5.62% | |||
| EBITDA | -31.42% | 5.63% | |||
| EPS Basic | -35.66% | 35.37% | |||
| Normalized Basic EPS | -35.68% | 24.59% | |||
| EPS Diluted | -35.66% | 35.37% | |||
| Normalized Diluted EPS | -35.68% | 24.59% | |||
| Average Basic Shares Outstanding | 0.12% | 19.18% | |||
| Average Diluted Shares Outstanding | 0.12% | 19.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||